Conference Coverage

Upfront NGS testing of metastatic NSCLC saves money, time

Publish date: May 17, 2018

 

REPORTING FROM THE ASCO ANNUAL MEETING

SOURCE: Pennell et al., ASCO Annual Meeting Abstract 9031.

Pages

Recommended Reading

FDA approves osimertinib for first-line advanced EGFR-mutated NSCLC
MDedge Hematology and Oncology
Screening tool IDs older NSCLC patients suitable for SBRT
MDedge Hematology and Oncology
ALUR: Alectinib topped chemo in pretreated ALK-positive NSCLC
MDedge Hematology and Oncology
Isolated ocular metastases from lung cancer
MDedge Hematology and Oncology
Bevacizumab-awwb becomes first biosimilar approved for cancer treatment
MDedge Hematology and Oncology
Qualitative assessment of organizational barriers to optimal lung cancer care in a community hospital setting in the United States
MDedge Hematology and Oncology
Checkpoint inhibitors get to patients quickly
MDedge Hematology and Oncology
Delay of NSCLC surgery can lead to worse prognosis
MDedge Hematology and Oncology
E-cigarette usage has changed
MDedge Hematology and Oncology
Is cancer immunotherapy more effective in men than women?
MDedge Hematology and Oncology